Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
This trial has been completed.
|Condition||chronic obstructive pulmonary disease (copd)|
|Sponsor||Theravance Biopharma R & D, Inc.|
|Start date||September 2015|
|End date||August 2016|
|Trial size||645 participants|
|Trial identifier||NCT02512510, 0127|
The purpose of this study is to measure the effectiveness and safety of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to placebo, a treatment without activity.
|Endpoint classification||safety/efficacy study|
|Intervention model||parallel assignment|
|Masking||double blind (subject, caregiver, investigator)|
Pulmonary function test following 12 weeks of treatment
time frame: 3 month pulmonary function test
Male or female participants at least 40 years old.
Inclusion Criteria: - Subject is a male or female subject 40 years of age or older Exclusion Criteria: - Females who are pregnant, lactating, breast-feeding or planning to become pregnant during the study
|Official title||A Phase 3, 12-week, Randomized, Double-blind Placebo-controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease|
Call for more information